Diagnos (ADK) AI Stock Analysis

• Market Cap: C$28.52M
• Dividend Yield: N/A
• Average Volume (3M): 246.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.33
• Revenue Growth: -39.00%
• EPS Growth: -11.21%
• Country: CA
• Employees: 16
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.01
• Shares Outstanding: 101,862,976
• 10 Day Avg. Volume: 231,805
• 30 Day Avg. Volume: 246,398
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Diagnos's overall stock score is primarily influenced by its severe financial challenges, which pose significant risks. However, strategic corporate events and moderate technical momentum provide some positive outlook, slightly offsetting the poor financial and valuation positions.

Diagnos Business Overview & Revenue Model

Company Description

DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. The company was founded in 1998 and is headquartered in Brossard, Canada.

How the Company Makes Money

Diagnos makes money through a combination of direct sales and licensing of its AI-based diagnostic platforms to healthcare providers, clinics, and hospitals. The company generates revenue by offering subscription-based access to its software tools, which are used by medical professionals for early disease detection and management. Additionally, Diagnos may engage in strategic partnerships with healthcare organizations and insurance companies to expand the reach and adoption of its technology. These partnerships can include revenue-sharing arrangements or joint ventures that contribute to its earnings.

Diagnos Financial Statement Overview

Summary

Diagnos is experiencing severe financial distress with ongoing losses as evidenced by negative gross and net profit margins. The balance sheet shows high leverage and negative equity in some periods, and cash flows exhibit persistent negative operating cash flows, indicating significant financial and operational challenges.

Income Statement

Diagnos has faced significant challenges in its income statement, with consistent negative gross profit margins over the years, indicating that the cost of goods sold exceeds revenue. The net profit margins are deeply negative, reflecting ongoing losses. Revenue has shown volatility, with recent declines from previous periods, further exacerbating financial instability. The EBIT and EBITDA margins are also negative, suggesting operational inefficiencies.

Balance Sheet

The balance sheet reveals financial stress with high leverage as indicated by the debt-to-equity ratio. Stockholders' equity is negative in some years, pointing to a difficult financial position. The equity ratio is low, indicating a reliance on debt financing. These factors imply potential risks in financial stability and solvency.

Cash Flow

Cash flow analysis shows persistent negative operating cash flows, indicating challenges in generating cash from operations. Free cash flow remains negative, exacerbating liquidity concerns. Financing cash flows are positive, suggesting reliance on external financing to sustain operations. Overall, cash flow management appears strained with little improvement over time.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	103.80K	170.16K	438.83K	267.07K	331.52K
Gross Profit	-943.56K	35.80K	-418.30K	-347.53K	-473.45K
EBITDA	-3.56M	-2.45M	-2.10M	-2.45M	-1.93M
Net Income	-4.29M	-3.12M	-2.61M	-2.05M	-3.38M
Balance Sheet
Total Assets	3.64M	663.79K	1.54M	1.95M	2.43M
Cash, Cash Equivalents and Short-Term Investments	3.24M	219.01K	920.91K	1.36M	1.87M
Total Debt	3.07M	3.19M	1.19M	471.68K	337.55K
Total Liabilities	3.40M	3.72M	1.66M	818.19K	614.78K
Stockholders Equity	233.11K	-3.05M	-113.51K	1.13M	1.82M
Cash Flow
Free Cash Flow	-3.65M	-2.16M	-2.07M	-1.40M	-2.66M
Operating Cash Flow	-3.64M	-2.15M	-2.04M	-1.36M	-2.64M
Investing Cash Flow	-3.11M	-14.02K	503.52K	262.93K	-759.98K
Financing Cash Flow	6.62M	2.08M	1.60M	882.82K	3.83M

Diagnos Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ADK, the sentiment is Positive. The current price of 0.28 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.21, and above the 200-day MA of 0.28, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 68.77 is Neutral, neither overbought nor oversold. The STOCH value of 81.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ADK.

Diagnos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AIML	55 Neutral	C$8.67M	―	-244.35%	―	-71.31%	-53.11%
ADK	52 Neutral	C$28.52M	―	366.78%	―	-39.00%	-11.21%
Sector *	50 Neutral	AU$2.58B	2.96	5.87%	2.70%	36.78%	14.04%
TREIF	―	$26.31M	―	-507.20%	―	―	―
TELE	―	$7.59M	―		―	―	―
CHS	44 Neutral	C$11.49M	―	2.18%	―	7.65%	78.75%
UDOCF	―	$12.74M	―	-9999.00%	―	―	―

Diagnos Corporate Events

DIAGNOS Advances into U.S. Optometry Market with FDA Pre-Submission for CARA System

DIAGNOS Inc. has submitted a Pre-Submission to the U.S. FDA for its CARA System, marking a strategic move into the U.S. optometry market. The CARA System is an AI-driven platform that assists optometrists in detecting retinal and systemic diseases, enhancing efficiency and consistency in eye exams. With a robust dataset from 16 countries, the system aims to improve clinical decision-making and patient outcomes, potentially reshaping the optometry landscape.

DIAGNOS Strengthens US Advisory Board with Optometry Expert Dr. Barry Ginsberg

DIAGNOS has announced the addition of Dr. Barry A. Ginsberg, a veteran optometrist, to its Scientific Advisory Board in the United States. With over three decades of experience in various optometry settings, Dr. Ginsberg’s expertise in innovative product launches and ocular disease management is expected to enhance DIAGNOS’s market strategy and demonstrate the ROI of its AI-driven screening technology. This strategic move aligns with DIAGNOS’s recent expansion into the US market, marked by the opening of a new office in South Florida, and positions the company to tap into the growing demand for eye exams in the US.

Diagnos Strengthens US Market Position with New Advisory Board Member

Diagnos Inc., a leader in AI-driven healthcare solutions, has appointed Ed Weiner, a prominent figure in the optical industry, to its Advisory Board. This strategic move is expected to bolster Diagnos’s presence in the US optical market, leveraging Weiner’s extensive experience and connections. The company has also recently opened an office in South Florida to support its US operations, highlighting its commitment to expanding its market reach and addressing the growing demand for eye exams in the US.

Diagnos Inc. Strengthens US Market Strategy with New Advisory Board Member

Diagnos Inc. has announced the appointment of Dr. Tomas J. Philipson, a former White House Economic Adviser, to its Advisory Board, enhancing its strategic direction in the US market. This move is expected to bolster Diagnos’s market positioning in the healthcare sector, particularly in leveraging AI for eye health diagnostics, as the company expands its operations with a new office in South Florida to tap into the growing demand for eye exams.

DIAGNOS Engages Allele Capital for Strategic Advisory

DIAGNOS Inc. has engaged Allele Capital Partners to provide capital markets advisory and social media services. This partnership aims to refine DIAGNOS’s business strategy to optimize milestones and capital needs, ultimately enhancing shareholder value. The engagement is subject to TSX Venture Exchange acceptance and reflects DIAGNOS’s strategic efforts to strengthen its market position.

Diagnos Inc. Extends Convertible Debentures Maturity Date

Diagnos Inc. has announced an amendment to extend the maturity date of its $300,000 unsecured convertible debentures from May 18, 2025, to May 18, 2026. This decision, approved by the board of directors, aims to benefit the company and its shareholders, with all other provisions of the debentures remaining unchanged. The amendment is subject to TSX Venture Exchange acceptance and formal documentation execution, and it is exempt from certain valuation and minority approval requirements under MI 61-101 due to its limited impact on the company’s market capitalization.